Humalog Tempo Pen

Humalog Tempo Pen is a pre‑filled, disposable pen containing the rapid‑acting insulin analog insulin lispro. It delivers a subcutaneous dose of insulin lispro in a ready‑to‑use format, marketed in the European Union for prescription use. The pen provides a convenient method for patients with diabetes to administer insulin quickly after meals, supporting glycaemic control without requiring a vial or other syringe preparation.

Humalog Tempo Pen is indicated for the management of blood glucose in adults with diabetes who require rapid‑acting insulin.

- Type 1 diabetes mellitus for mealtime insulin coverage. - Type 2 diabetes mellitus when basal insulin alone does not achieve target glycaemia. - Adjunct to basal insulin regimens to provide flexible, on‑demand dosing. - Use in insulin‑pump transition periods when a rapid‑acting bolus is needed. - Situations requiring rapid glucose lowering, such as post‑prandial spikes.

Adverse reactions to Humalog Tempo Pen are reported across a range of frequencies and severities.

Common: - Mild hypoglycaemia (blood glucose <70 mg/dL) with symptoms such as shakiness, sweating, or hunger. - Injection site reactions including redness, swelling, or itching. - Lipodystrophy presenting as localized thickening or loss of subcutaneous fat. - Transient weight gain associated with improved glycaemic control. - Nausea or abdominal discomfort shortly after injection.

Serious: - Severe hypoglycaemia requiring assistance, with possible loss of consciousness or seizures. - Allergic reactions such as urticaria, angio‑edema, or anaphylaxis. - Persistent hyperglycaemia indicating possible insulin resistance or dosing error. - Hypersensitivity leading to respiratory distress or bronchospasm.

When prescribing or using Humalog Tempo Pen, clinicians and patients should consider several safety precautions to minimise risks.

- Verify the correct patient, insulin type, and dose before each injection. - Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced. - Monitor blood glucose closely during illness, pregnancy, or periods of altered food intake. - Educate patients on recognizing and treating hypoglycaemia promptly. - Store the pen at controlled room temperature; discard after the indicated in‑use period. - Avoid using the pen after the expiration date or if the solution appears discoloured. - Consider potential reduced sensitivity in patients with peripheral neuropathy affecting injection technique.

Humalog Tempo Pen may interact with other medicines, affecting glucose levels or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins or high‑dose insulin analogues, which can cause severe hypoglycaemia. - Beta‑blockers that mask hypoglycaemia symptoms, making detection difficult.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk. - Corticosteroids, which may raise blood glucose and require dose adjustments. - Diuretics, especially thiazides, that can affect electrolyte balance and glucose control. - Alcohol, which can cause delayed hypoglycaemia after insulin administration.